Gastroenteropancreatic neuroendocrine neoplasms (NENs) are a heterogenous group of tumors that are incurable when metastatic, regardless of grade. The aim of this article is to understand tumor heterogeneity and grade progression as possible contributors to drug resistance in gastroentropancreatic neuroendocrine tumors (GEP-NETs). Heterogeneity has been observed in the genetic, pathological, and imaging features of these tumors at baseline. Diagnostic challenges related to tumor sampling and the potential for changes in grade over time further confound our ability to optimize therapy for patients. A better understanding of NEN biology and tumor heterogeneity at baseline and over time could lead to the development of new therapeutic avenues.

More from our Archive

• DOI: 10.1001/jamaoncol.2023.1830 2023

  Vigorous Intermittent Lifestyle Physical Activity and Cancer Incidence Among Nonexercising Adults

  Emmanuel Stamatakis, Matthew N. Ahmadi, Christine M. Friedenreich, Joanna M. Blodgett, Annemarie Koster, Andreas Holtermann, Andrew Atkin, Vegar Rangul, Lauren B. Sherar, Armando Teixeira-Pinto, Ulf Ekelund, I-Min Lee, Mark Hamer

• DOI: 10.3390/cancers15153900 2023

  Steroidal Saponins: Naturally Occurring Compounds as Inhibitors of the Hallmarks of Cancer

  Salwa Bouabdallah, Amna Al-Maktoum, Amr Amin

• DOI: 10.4103/crst.crst_332_22 2023

  Artificial intelligence-based prediction of oral mucositis in patients with head-and-neck cancer: A prospective observational study utilizing a thermographic approach

  Ruchika Thukral, Ashwani Kumar Aggarwal, Ajat Shatru Arora, Tapas Dora, Sankalp Sancheti

• DOI: 10.3390/cancers15153886 2023

  Antibody–Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence

  Pooja Gogia, Hamza Ashraf, Sidharth Bhasin, Yiqing Xu

• DOI: 10.3390/cancers15143688 2023

  The First Cold Atmospheric Plasma Phase I Clinical Trial for the Treatment of Advanced Solid Tumors: A Novel Treatment Arm for Cancer

  Jerome Canady, Saravana R. K. Murthy, Taisen Zhuang, Steven Gitelis, Aviram Nissan, Lawan Ly, Olivia Z. Jones, Xiaoqian Cheng, Mohammad Adileh, Alan T. Blank, Matthew W. Colman, Keith Millikan, Cristina O’Donoghue, Kerstin M. Stenson, Karen Ohara, Gal Schtrechman, Michael Keidar, Giacomo Basadonna

• DOI: 10.1001/jamaoncol.2023.2751 2023

  Neoadjuvant Camrelizumab Plus Platinum-Based Chemotherapy vs Chemotherapy Alone for Chinese Patients With Resectable Stage IIIA or IIIB (T3N2) Non–Small Cell Lung Cancer

  Jie Lei, Jinbo Zhao, Li Gong, Yunfeng Ni, Yongan Zhou, Feng Tian, Honggang Liu, Zhongping Gu, Lijun Huang, Qiang Lu, Xiaoping Wang, Jianyong Sun, Ende Yang, Tao Wang, Daixing Zhong, Jian Wang, Zhengwei Zhao, Zhigang Liu, Cheng Wang, Xiaojing Wang, Guangyan Lei, Xiaolong Yan, Tao Jiang

• DOI: 10.1200/jco.23.00062 2023

  Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer

  Nanda Horeweg, Remi A. Nout, Ina M. Jürgenliemk-Schulz, Ludy C.H.W. Lutgens, Jan J. Jobsen, Marie A.D. Haverkort, Jan Willem M. Mens, Annerie Slot, Bastiaan G. Wortman, Stephanie M. de Boer, Ellen Stelloo, Karen W. Verhoeven-Adema, Hein Putter, Vincent T.H.B.M. Smit, Tjalling Bosse, Carien L. Creutzberg, C.L. Creutzberg, P.C.M. Koper, W.L.J. van Putten, R. Dercksen, M. van Lent, H. Beerman, M.L.M. Lybeert, J.J. Jobsen, J.H. Meerwaldt, C.C. Wárlám-Rodenhuis, K.A.J. De Winter, L.C.H.W. Lutgens, A.C.M. van den Bergh, E.M. van de Steen-Banasik, M.C. Stenfert Kroese, L.A.M. Pop, L. Uitterhoeve, A.A. Snijders-Keilholz, B.N.F.M. van Bunningen, J.H. Biesta, F.M. Gescher, J. Pomp, O.W.M. Meijer, J.H. Tabak, A. Slot, I.M. Jürgenliemk-Schulz, E.M. van der Steen-Banasik, J.W.M. Mens, R.A. Nout, V.T.H.B.M. Smit, J.W. Leer, P.R. Timmer, B. van Triest, B. Pras, R. Wiggenraad, F. Gescher, V.L.M. Coen,

• DOI: 10.1200/jco.23.00725 2023

  Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer

  Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, Katherine Murphy, Thiraviyam Elumalai, Manjusha Soni, Alexandra Ferrera, Charlotte Richardson, Richard Walshaw, Hitesh Mistry, Vijay Ramani, Yeepei Song, Alison Birtle, Ann Henry, Joachim Chan, Peter Hoskin, Ananya Choudhury

• DOI: 10.1200/jco.23.00512 2023

  Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future

  Sarah A. Holstein, Shakira J. Grant, Tanya M. Wildes

• DOI: 10.1158/1078-0432.ccr-23-0092 2023

  Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

  Maria Vieito, Victor Moreno, Anna Spreafico, Irene Brana, Judy S. Wang, Meir Preis, Tatiana Hernández, Sofia Genta, Aaron R. Hansen, Bernard Doger, Vladimir Galvao, Laurie Lenox, Regina J. Brown, Anna Kalota, Jaydeep Mehta, Friederike Pastore, Bharvin Patel, Pankaj Mistry, Junchen Gu, Josh Lauring, Manish R. Patel